These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 27494817)

  • 1. Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.
    Girard R; Fam MD; Zeineddine HA; Tan H; Mikati AG; Shi C; Jesselson M; Shenkar R; Wu M; Cao Y; Hobson N; Larsson HBW; Christoforidis GA; Awad IA
    J Neurosurg; 2017 Jul; 127(1):102-110. PubMed ID: 27494817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.
    Zeineddine HA; Girard R; Cao Y; Hobson N; Fam MD; Stadnik A; Tan H; Shen J; Chaudagar K; Shenkar R; Thompson RE; McBee N; Hanley D; Carroll T; Christoforidis GA; Awad IA
    J Magn Reson Imaging; 2018 Apr; 47(4):1133-1138. PubMed ID: 28791783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic permeability and quantitative susceptibility: related imaging biomarkers in cerebral cavernous malformations.
    Mikati AG; Tan H; Shenkar R; Li L; Zhang L; Guo X; Larsson HB; Shi C; Liu T; Wang Y; Shah A; Edelman RR; Christoforidis G; Awad I
    Stroke; 2014 Feb; 45(2):598-601. PubMed ID: 24302484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular permeability in cerebral cavernous malformations.
    Mikati AG; Khanna O; Zhang L; Girard R; Shenkar R; Guo X; Shah A; Larsson HB; Tan H; Li L; Wishnoff MS; Shi C; Christoforidis GA; Awad IA
    J Cereb Blood Flow Metab; 2015 Oct; 35(10):1632-9. PubMed ID: 25966944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Susceptibility Mapping in Cerebral Cavernous Malformations: Clinical Correlations.
    Tan H; Zhang L; Mikati AG; Girard R; Khanna O; Fam MD; Liu T; Wang Y; Edelman RR; Christoforidis G; Awad IA
    AJNR Am J Neuroradiol; 2016 Jul; 37(7):1209-15. PubMed ID: 26965464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trial Readiness of Cavernous Malformations With Symptomatic Hemorrhage, Part II: Biomarkers and Trial Modeling.
    Hage S; Kinkade S; Girard R; Flemming KD; Kim H; Torbey MT; Huang J; Huston J; Shu Y; Selwyn RG; Hart BL; Mabray MC; Feghali J; Sair HI; Narvid J; Lupo JM; Lee J; Stadnik A; Alcazar-Felix RJ; Shenkar R; Hobson N; DeBiasse D; Lane K; McBee NA; Treine K; Ostapkovich N; Wang Y; Thompson RE; Koenig JI; Carroll T; Hanley DF; Awad IA
    Stroke; 2024 Jan; 55(1):31-39. PubMed ID: 38134265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of iron content in human cerebral cavernous malformation using quantitative susceptibility mapping.
    Tan H; Liu T; Wu Y; Thacker J; Shenkar R; Mikati AG; Shi C; Dykstra C; Wang Y; Prasad PV; Edelman RR; Awad IA
    Invest Radiol; 2014 Jul; 49(7):498-504. PubMed ID: 24619210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnetic susceptibility as a 1-year predictor of outcome in familial cerebral cavernous malformations: a pilot study.
    Incerti I; Fusco M; Contarino VE; Siggillino S; Conte G; Lanfranconi S; Bertani GA; Gaudino C; d'Orio P; Pallini R; D'Alessandris QG; Meessen JMTA; Nicolis EB; Vasamì A; Dejana E; Bianchi AM; Triulzi FM; Latini R; Scola E
    Eur Radiol; 2023 Jun; 33(6):4158-4166. PubMed ID: 36602570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliable? The Value of Early Postoperative Magnetic Resonance Imaging after Cerebral Cavernous Malformation Surgery.
    Chen B; Göricke S; Wrede K; Jabbarli R; Wälchli T; Jägersberg M; Sure U; Dammann P
    World Neurosurg; 2017 Jul; 103():138-144. PubMed ID: 28391022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of the venous angioarchitecture of multiple cerebral cavernous malformations with familial or sporadic disease: a susceptibility-weighted imaging study with 7-Tesla MRI.
    Dammann P; Wrede K; Zhu Y; Matsushige T; Maderwald S; Umutlu L; Quick HH; Hehr U; Rath M; Ladd ME; Felbor U; Sure U
    J Neurosurg; 2017 Feb; 126(2):570-577. PubMed ID: 27153162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol for familial cerebral cavernous malformation (Treat_CCM): study protocol for a randomized controlled pilot trial.
    Lanfranconi S; Scola E; Bertani GA; Zarino B; Pallini R; d'Alessandris G; Mazzon E; Marino S; Carriero MR; Scelzo E; Faragò G; Castori M; Fusco C; Petracca A; d'Agruma L; Tassi L; d'Orio P; Lampugnani MG; Nicolis EB; Vasamì A; Novelli D; Torri V; Meessen JMTA; Al-Shahi Salman R; Dejana E; Latini R;
    Trials; 2020 May; 21(1):401. PubMed ID: 32398113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).
    Girard R; Li Y; Stadnik A; Shenkar R; Hobson N; Romanos S; Srinath A; Moore T; Lightle R; Shkoukani A; Akers A; Carroll T; Christoforidis GA; Koenig JI; Lee C; Piedad K; Greenberg SM; Kim H; Flemming KD; Ji Y; Awad IA
    Neurosurgery; 2021 Feb; 88(3):686-697. PubMed ID: 33469662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical imaging changes in cerebral cavernous angiomas during prospective surveillance.
    Carrión-Penagos J; Zeineddine HA; Polster SP; Girard R; Lyne SB; Koskimäki J; Romanos S; Srinath A; Zhang D; Cao Y; Stadnik A; Piedad K; Shenkar R; Awad IA
    J Neurosurg; 2021 Mar; 134(3):1147-1154. PubMed ID: 32244216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroimaging of Cavernous Malformations.
    Mokin M; Agazzi S; Dawson L; Primiani CT
    Curr Pain Headache Rep; 2017 Oct; 21(12):47. PubMed ID: 29030748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial.
    Polster SP; Stadnik A; Akers AL; Cao Y; Christoforidis GA; Fam MD; Flemming KD; Girard R; Hobson N; Koenig JI; Koskimäki J; Lane K; Liao JK; Lee C; Lyne SB; McBee N; Morrison L; Piedad K; Shenkar R; Sorrentino M; Thompson RE; Whitehead KJ; Zeineddine HA; Hanley DF; Awad IA
    Neurosurgery; 2019 Dec; 85(6):843-853. PubMed ID: 30476251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth.
    Girard R; Zeineddine HA; Koskimäki J; Fam MD; Cao Y; Shi C; Moore T; Lightle R; Stadnik A; Chaudagar K; Polster S; Shenkar R; Duggan R; Leclerc D; Whitehead KJ; Li DY; Awad IA
    Circ Res; 2018 Jun; 122(12):1716-1721. PubMed ID: 29720384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Common transcriptome, plasma molecules, and imaging signatures in the aging brain and a Mendelian neurovascular disease, cerebral cavernous malformation.
    Koskimäki J; Polster SP; Li Y; Romanos S; Srinath A; Zhang D; Carrión-Penagos J; Lightle R; Moore T; Lyne SB; Stadnik A; Piedad K; Cao Y; Shenkar R; Dimov AV; Hobson N; Christoforidis GA; Carroll T; Girard R; Awad IA
    Geroscience; 2020 Oct; 42(5):1351-1363. PubMed ID: 32556941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased iron deposition of deep cerebral gray matter structures in hemodialysis patients: A longitudinal study using quantitative susceptibility mapping.
    Chai C; Wang H; Liu S; Chu ZQ; Li J; Qian T; Haacke EM; Xia S; Shen W
    J Magn Reson Imaging; 2019 Mar; 49(3):786-799. PubMed ID: 30291651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline Characteristics of Patients With Cavernous Angiomas With Symptomatic Hemorrhage in Multisite Trial Readiness Project.
    Kim H; Flemming KD; Nelson JA; Lui A; Majersik JJ; Cruz MD; Zabramski J; Trevizo O; Lanzino G; Zafar A; Torbey M; Mabray MC; Robinson M; Narvid J; Lupo J; Thompson RE; Hanley DF; McBee N; Treine K; Ostapkovich N; Stadnik A; Piedad K; Hobson N; Carroll T; Shkoukani A; Carrión-Penagos J; Mendoza-Puccini C; Koenig JI; Awad I
    Stroke; 2021 Dec; 52(12):3829-3838. PubMed ID: 34525838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phantom validation of quantitative susceptibility and dynamic contrast-enhanced permeability MR sequences across instruments and sites.
    Hobson N; Polster SP; Cao Y; Flemming K; Shu Y; Huston J; Gerrard CY; Selwyn R; Mabray M; Zafar A; Girard R; Carrión-Penagos J; Chen YF; Parrish T; Zhou XJ; Koenig JI; Shenkar R; Stadnik A; Koskimäki J; Dimov A; Turley D; Carroll T; Awad IA
    J Magn Reson Imaging; 2020 Apr; 51(4):1192-1199. PubMed ID: 31515878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.